Safety Risks in the Clinical Application of iPS Cells
First written in FY2018-Q1. 22 of 23 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「Although ensuring safety is the main challenge in the clinical application of iPS cells, our group has developed and owns RNA reprogramming technology for producing high-quality iPS cells optimised for clinical application.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2026-H1RestatedAnnual report
「Although ensuring safety is the main challenge in the clinical application of iPS cells, our group has developed and owns RNA reprogramming technology for producing high-quality iPS cells optimised for clinical application.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2025-H1RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
The safety issues associated with the clinical application of iPS cells and the response through RNA reprogramming technology have been reaffirmed. - FY2024-Q3RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2023-Q3RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
The safety issues associated with the clinical application of iPS cells and the response through technology that suppresses the risks of genetic mutations and residual exogenous genes and viruses have been reaffirmed. - FY2023-Q2RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2023-Q1RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2022-Q3RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2022-Q1RestatedAnnual report
「Although the greatest technical challenge in applying iPS cells to medicine is ensuring safety, we have developed and own “RNA reprogramming technology” for producing high-quality iPS cells suitable for clinical application, while minimising the risk of genetic mutations and reducing the risk of residual exogenous genes and viruses.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2021RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2021-Q3RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
The safety risks associated with the clinical application of iPS cells, as well as the response through RNA reprogramming technology, have been reaffirmed. - FY2021-Q2RestatedAnnual report
「Meanwhile, the greatest technical challenge in the clinical application of iPS cells is said to be ensuring safety, including reducing the risk of tumorigenesis.」
The recognition that ensuring safety, including reducing the risk of tumorigenesis, is the greatest technical challenge in the clinical application of iPS cells has been reaffirmed. - FY2021-Q1RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
The safety risks associated with the clinical application of iPS cells, as well as the response through RNA reprogramming technology, have been reaffirmed. - FY2020RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
The safety risks of genetic mutations and residual exogenous factors and viruses in iPS cells, as well as the response through RNA reprogramming technology, have been reaffirmed. - FY2020-Q3RestatedAnnual report
「Meanwhile, the greatest technical challenge in the clinical application of iPS cells is said to be ensuring safety, including reducing the risk of tumorigenesis.」
The recognition that ensuring safety, including reducing the risk of tumorigenesis, is the greatest technical challenge in the clinical application of iPS cells has been reaffirmed. - FY2020-Q2RestatedAnnual report
「Meanwhile, the greatest technical challenge in the clinical application of iPS cells is said to be ensuring safety, including reducing the risk of tumorigenesis.」
The recognition that ensuring safety, including reducing the risk of tumorigenesis, is the greatest technical challenge in the clinical application of iPS cells has been reaffirmed. - FY2020-Q1RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
The safety issues associated with genetic mutations and residual exogenous factors and viruses in the medical application of iPS cells, as well as the response through RNA reprogramming technology, have been reaffirmed. - FY2019-Q3RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. Risks include genetic mutations and tumorigenesis caused by residual exogenous factors.」
The risks of genetic mutations, residual exogenous factors, and tumorigenesis have been reaffirmed as the greatest technical challenges in the medical application of iPS cells. - FY2019-Q2RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. Risks include genetic mutations and tumorigenesis caused by residual exogenous factors.」
The risks of genetic mutations, residual exogenous factors, and tumorigenesis have been reaffirmed as the greatest technical challenges in the medical application of iPS cells. - FY2019-Q1RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. Risks include genetic mutations and tumorigenesis caused by residual exogenous factors.」
The risks of genetic mutations, residual exogenous factors, and tumorigenesis have been reaffirmed as the greatest technical challenges in the medical application of iPS cells. - FY2018RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. Risks include genetic mutations and tumorigenesis caused by residual exogenous factors in the iPS cells.」
The risks of genetic mutations, residual exogenous factors, and tumorigenesis have been reaffirmed as the greatest technical challenges in the clinical application of iPS cells. - FY2018-Q3RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. Risks include genetic mutations and tumorigenesis caused by residual exogenous genes or viruses in the iPS cells.」
The risks of genetic mutations, residual exogenous genes and viruses, and tumorigenesis have been reaffirmed as the greatest technical challenges in the clinical application of iPS cells. - FY2018-Q1First statedAnnual report
「Ensuring safety is cited as the greatest technical challenge in the clinical application of iPS cells. Risks include genetic mutations that may occur when iPS cells are produced from skin or blood, and the risk of tumorigenesis caused by residual exogenous genes or viruses in the iPS cells.」
The risks of genetic mutations, residual exogenous genes and viruses, and tumorigenesis associated with the clinical application of iPS cells were identified as the greatest technical challenges in clinical applications.